Strategies to overcome the main challenges of the use of CRISPR/Cas9 as a replacement for cancer therapy
Mohammed Fatih Rasul, Bashdar Mahmud Hussen, Abbas Salihi, Bnar Saleh Ismael, Paywast Jamal Jalal, Anna Zanichelli, Elena Jamali, Aria Baniahmad, Soudeh Ghafouri‐Fard, Abbas Basiri, Mohammad Taheri
Abstract
CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats-associated protein 9) shows the opportunity to treat a diverse array of untreated various genetic and complicated disorders. Therapeutic genome editing processes that target disease-causing genes or mutant genes have been greatly accelerated in recent years as a consequence of improvements in sequence-specific nuclease technology. However, the therapeutic promise of genome editing has yet to be explored entirely, many challenges persist that increase the risk of further mutations. Here, we highlighted the main challenges facing CRISPR/Cas9-based treatments and proposed strategies to overcome these limitations, for further enhancing this revolutionary novel therapeutics to improve long-term treatment outcome human health.